Entity

Immunotherapy

Cancer treatment that trains the patient's own immune system to attack tumors.

As of 9 Nov 2026Last evidence 9 Nov 2026

What is happening now

  • Samsung Bioepis Puts Keytruda Biosimilar Into FDA Review With Full Phase 3 Lung Cancer Trial Data

    Reported claim · first reported 7 Nov 2026 · 1 claim · best-carried claim: 3 separate publishers

All 1 event and claims involving Immunotherapy

What changed

  • Attention Rising: 42 mentions on 9 Nov 2026, against 22 on 19 Oct 2026 (+91%).
  • State No change in coverage state or wire tier recorded since 3 Nov 2026.
  • Claims No claim first reported since 8 Nov 2026.

How well we know this

893 documents · 179 publishers · 5% say something specific about it · last evidence 9 Nov 2026

  • Gap: 5% of mentions say something specific about it; the rest only name it

In this snapshot’s daily coverage:

Reported alongside Immunotherapy

Names most often reported alongside it; bigger circles and heavier lines mean more shared documents. A dashed circle has no page of its own yet.

Colorectal Canc…ChinaAI
  • Colorectal Cancer · 381 shared documents
  • Overall Survival · 208 shared documents · no page of its own yet
  • FDA · 191 shared documents · no page of its own yet
  • Lung Cancer · 182 shared documents · no page of its own yet
  • Clinical Trial · 138 shared documents · no page of its own yet
  • China · 133 shared documents
  • Clinical Trials · 123 shared documents · no page of its own yet
  • AI · 121 shared documents
  • T-Cell · 119 shared documents · no page of its own yet
  • Cancer Cells · 113 shared documents · no page of its own yet

Story momentum

Rising

The word compares 42 mentions on 9 Nov 2026 with 22 on 19 Oct 2026 (+91%); a change of less than 8% either way reads Steady.

Daily mentions +45% from 25 Sept 2026 to 9 Nov 2026, between 11 and 53 a day

How often tracked coverage mentions Immunotherapy, day by day.

Market price, cited

Not priced yet

No open prediction market prices a question materially about Immunotherapy yet. Ask about Immunotherapy

No market price on file: no prediction market prices a question about this name yet

Coverage volume and market price are separate measures.

For developers

This page is also an object: GET https://sigb.ai/api/v1/node/e/e20001c47e40d4b109d5f837 returns the same record as sb.node.v1. Or call the get_entity MCP tool at https://sigb.ai/api/mcp with name immunotherapy.

{
  "name": "immunotherapy",
  "label": "Immunotherapy",
  "asOf": "2026-11-09",
  "mentions": 79,
  "outlets": 59,
  "domains": 12,
  "node": {
    "id": "sb:e/e20001c47e40d4b109d5f837",
    "schema": "sb.node.v1",
    "rest": "https://sigb.ai/api/v1/node/e/e20001c47e40d4b109d5f837",
    "knowledgeCutoff": "2026-11-09T23:25:51.141948+00:00",
    "snapshot": "this deploy's committed data files (commit not exposed in this runtime)"
  },
  "coverageTrend": "rising",
  "history": {
    "since": "2026-11-03T13:08:56.552092+00:00",
    "changes": 0
  },
  "whereFrom": {
    "level": "counts",
    "label": "79 mentions across 12 domains",
    "children": [
      {
        "level": "reports",
        "label": "6 reports drawn on this page, each with its link",
        "children": {
          "count": 6,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "domains",
        "label": "12 coverage domains",
        "children": {
          "count": 12,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "not shown",
        "label": "The other 73 mentions",
        "edge": "counted daily from tracked coverage; single mentions are not listed one by one"
      }
    ]
  }
}

The figures on this page, as data. The tool returns the full entity record.

Events involving Immunotherapy

Most-reported first, then newest. Registered events come from the event record; reported events are groups of claims about one occurrence. Claims are grouped when they were first reported within 2 days of each other and either name at least 2 of the same people, places or things besides this one, or share at least 25% of their wording. Each claim keeps its own record.

  • Samsung Bioepis Puts Keytruda Biosimilar Into FDA Review With Full Phase 3 Lung Cancer Trial Data

    Reported claim · first reported 7 Nov 2026 · 1 claim · best-carried claim: 3 separate publishers

    corroborated

Walk the record from Immunotherapy

Open where it comes from, follow a claim or a related name, and use the trail to come back. Every step says what it is, how it stands and when. Machines read the same record.

Immunotherapy

Entity.

Evidence
893 documents · 179 separate publishers · a mention shows the name is in use, not that any claim about it is true
Standing
A name from our starting list; its record is kept up to date automatically from coverage
Time
first seen 11 Mar 2026, last seen 9 Nov 2026
Measured
5% of mentions say something specific about it; the rest only name it
As of
9 Nov 2026
11 links from here

Who it moves with: the 10 names are in the map above.

What is claimed about it (1)

  • Corroborated: Reported by three or more sources that did not copy each other.

Situations it is named in (0)

none on file at this cutoff

For machines: this record as JSON

Watch this

What the coverage says

Recent reporting that names Immunotherapy, newest first. Open any row to follow it to the original article.

Evidence tiers: primary source = an official public record · attributed = a named outlet, receipt linked · lead = observed, not yet receipted.

What it connects to

Related records.

Recorded history

No change in coverage state or wire tier recorded since 3 Nov 2026.

Ask about ImmunotherapyWatch Immunotherapy

Story momentum counts mentions in tracked coverage. Prices are the market’s own, cited with the venue. Informational only, not advice. As of 9 Nov 2026.